Biobanks of human & population samples

Biobanks of human and population samples are the physical infrastructure — consent, collection, cryopreservation, cataloguing, storage and distribution — that turns blood, tissue and DNA specimens from hundreds of thousands of participants into a usable research and clinical resource, distinct from the genomic data repositories and databases built on top of that biospecimen collection. UK Biobank has recruited and follows roughly 500,000 UK participants, and its linked biospecimens and health data underpin a continuous stream of published genomic and epidemiological research. BioLife Solutions supplies the biopreservation media and cold-chain technology (CryoStor, BloodStor, CellSeal CryoCase) that biobanks and cell/gene-therapy manufacturers depend on to keep specimens viable through freeze, storage and thaw. Discovery Life Sciences procures and processes human biospecimens — including legacy specimen collections it calls the “Vintage Collection” — as a service for pharma and biotech genomic-biomarker and companion-diagnostic programs. The China National GeneBank (CNGB), operated in Shenzhen, is one of the world’s largest biological-resource repositories. In India, the government inaugurated the Phenome-India National Biobank at CSIR-IGIB in 2025, launching the country’s own longitudinal population-scale biospecimen and phenotype data study.

The key directions of biobanks of human and population samples are:

1. Population biobanking (Population Biobanking): large-scale, consented biospecimen and health-data cohorts recruited for long-term research use — UK Biobank, Phenome-India National Biobank.
2. Biopreservation technology (Biopreservation Media): cryopreservation media, cold-chain packaging and freeze/thaw protocols keeping specimens and cell/gene-therapy products viable — BioLife Solutions.
3. Biospecimen procurement services (Biospecimen Procurement): contract collection, processing and supply of human biospecimens for pharma/biotech research programs — Discovery Life Sciences.
4. National biobank infrastructure (National Biobank Infrastructure): government- or state-affiliated large-scale repositories serving as a country’s standing biological-resource base — China National GeneBank.

Sectoral value chain#

[consent & sample collection] ──> [processing & cryopreservation] ──> [cataloguing & data linkage]
                                                    │
                                       (cold-chain storage maintenance)
                                                    │
                                                    ▼
[longitudinal data linkage & re-consent] <─── [distribution to researchers/pharma] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Population cohort biobanking (Population Biobanking): large, consented cohorts (UK Biobank’s roughly 500,000 participants) linked to health records provide the statistical power for genome-wide association and epidemiological studies.
• Biopreservation media (Biopreservation Media): validated cryoprotectant formulations (BioLife Solutions’ CryoStor/BloodStor) control ice-crystal formation and osmotic stress during freeze/thaw to keep cells and tissue viable.
• Biospecimen procurement networks (Biospecimen Procurement): contract specimen-sourcing networks (Discovery Life Sciences) supply pharma biomarker-discovery and companion-diagnostic development programs with consented, annotated human tissue.

The stack pairs population-scale cohort recruitment and consent infrastructure with validated cryopreservation chemistry and cold-chain logistics to keep specimens usable for research decades after collection.

1. Population cohort recruitment and linkage (Population Biobanking):
   • UK Biobank and the newly launched Phenome-India National Biobank recruit large, consented participant cohorts and link their biospecimens to longitudinal health and phenotype records, the statistical foundation for genome-wide association studies.
2. Cryopreservation chemistry (Biopreservation Media):
   • BioLife Solutions’ CryoStor and BloodStor media control ice-crystal formation and osmotic stress during freezing, and CellSeal CryoCase packaging maintains cold-chain integrity during transport.
3. Contract biospecimen procurement (Biospecimen Procurement):
   • Discovery Life Sciences sources, processes and annotates human biospecimens (including legacy “Vintage Collection” material) to supply pharma genomic-biomarker discovery and companion-diagnostic development pipelines.
4. National biobank infrastructure (National Biobank Infrastructure):
   • The China National GeneBank and India’s Phenome-India National Biobank represent government-backed, large-scale repository infrastructure intended as a standing national biological-resource base rather than a single research project.